Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

CRVO

CervoMed Inc

Nov 20 • 04:00PM ET

9.01

+0.40 4.59 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB NBIX ACAD ITCI CYTK BTAI CORT INVA LGVN CYPH

| Held by: VTI VXF IWC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.90	Insider Own	31.44%	Shs Outstand	9.25M	Perf Week	24.28%
Market Cap	83.36M	Forward P/E	-	EPS next Y	-1.98	Insider Trans	3.27%	Shs Float	6.34M	Perf Month	26.19%
Enterprise Value	56.07M	PEG	-	EPS next Q	-0.64	Inst Own	23.34%	Short Float	2.59%	Perf Quarter	-1.31%
Income	-25.58M	P/S	13.53	EPS this Y	-32.46%	Inst Trans	12.77%	Short Ratio	1.66	Perf Half Y	7.01%
Sales	6.16M	P/B	3.21	EPS next Y	25.88%	ROA	-64.37%	Short Interest	0.16M	Perf YTD	285.04%
Book/sh	2.81	P/C	3.05	EPS next 5Y	4.79%	ROE	-71.42%	52W High	16.94 -46.81%	Perf Year	-13.45%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	52.23% 56.66%	ROIC	-98.36%	52W Low	1.80 400.56%	Perf 3Y	5.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.08% 6.79%	Perf 5Y	-83.08%
Dividend TTM	-	EV/Sales	9.10	EPS Y/Y TTM	-76.96%	Oper. Margin	-441.64%	ATR (14)	0.57	Perf 10Y	-99.95%
Dividend Ex-Date	-	Quick Ratio	6.60	Sales Y/Y TTM	-38.81%	Profit Margin	-415.36%	RSI (14)	70.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.60	EPS Q/Q	-52.89%	SMA20	21.92%	Beta	-0.94	Target Price	22.43
Payout	-	Debt/Eq	0.00	Sales Q/Q	-83.37%	SMA50	15.70%	Rel Volume	1.39	Prev Close	8.61
Employees	15	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	SMA200	17.16%	Avg Volume	98.79K	Price	9.01
IPO	Oct 17, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	-27.83% -73.43%	Trades		Volume	137,241	Change	4.59%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy	$14
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy	$45
Dec-05-24	Initiated	H.C. Wainwright	Buy	$42
Sep-18-24	Initiated	Chardan Capital Markets	Buy	$55
Jul-26-24	Initiated	Morgan Stanley	Overweight	$35
Feb-15-24	Initiated	Canaccord Genuity	Buy	$50
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy	$1.25

Show Previous Ratings

Nov-10-25 07:00AM	CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-07-25 05:55PM	CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.08%
06:45AM	Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? (Zacks)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:00AM	CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies (GlobeNewswire)
08:00AM	Loading…
Oct-28-25 08:00AM	CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley (GlobeNewswire)
Oct-20-25 08:00AM	CervoMed to Present at the Emerging Growth Conference (GlobeNewswire) +6.07%
Oct-16-25 08:05AM	Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? (Zacks) -6.17%
Oct-08-25 07:00AM	CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies (GlobeNewswire)
Oct-07-25 08:00AM	CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer (GlobeNewswire)
Oct-02-25 08:00AM	CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-18-25 07:35AM	CervoMed announces development program, benefits of neflamapimod (TipRanks)
Sep-17-25 07:30AM	CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference (GlobeNewswire)
Sep-03-25 08:00AM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.89%
Aug-11-25 08:00AM	CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
05:40PM	Loading…
Aug-07-25 05:40PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +5.46%
Aug-06-25 05:55PM	Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-05-25 08:00AM	CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +7.72%
Jul-31-25 09:15AM	Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-28-25 09:05AM	CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains? (Zacks)
07:00AM	CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration (GlobeNewswire)
Jul-24-25 04:05PM	CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025 (GlobeNewswire) +11.55%
Jul-09-25 07:20AM	CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3 (Insider Monkey) +5.31%
Jul-08-25 07:00AM	CervoMed Announces Late-Breaking Presentations at Alzheimer's Association International Congress 2025 (GlobeNewswire) +7.41%
Jun-10-25 08:00AM	CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization (GlobeNewswire)
May-12-25 09:15AM	CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.18%
08:00AM	CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-07-25 08:00AM	CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire) -5.01%
Apr-02-25 07:00AM	Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 (GlobeNewswire) +36.07%
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha)
08:00AM	Loading…
Mar-25-25 08:00AM	CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD ) (GlobeNewswire) -17.37%
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
02:55AM	CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats (SeekingAlpha)
Mar-19-25 04:27PM	Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? (Insider Monkey) +23.37%
Mar-18-25 04:48AM	CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now (Insider Monkey)
Mar-17-25 08:00AM	CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +40.53%
07:28AM	Why CervoMed Inc. (CRVO) Soared Last Week? (Insider Monkey)
Mar-14-25 11:25AM	CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program (TipRanks) +11.23%
Mar-10-25 04:05PM	CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies (GlobeNewswire) +6.31%
Feb-19-25 02:09PM	Why CervoMed (CRVO) Is Advancing Today (Insider Monkey)
Jan-31-25 08:00AM	CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Jan-29-25 08:00AM	CervoMed to Present at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Dec-12-24 07:45AM	CervoMed price target lowered to $4 from $45 at Roth MKM (TipRanks)
07:00AM	CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-24 07:16AM	CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint (TipRanks) -9.72%
Dec-10-24 11:37AM	CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets (Benzinga) -78.93%
07:00AM	CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies (GlobeNewswire)
Nov-28-24 07:17AM	CervoMeds stock rises as FDA grants orphan drug status to dementia drug (Pharmaceutical Technology)
Nov-27-24 07:00AM	CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia (GlobeNewswire) +14.72%
Nov-13-24 08:00AM	CervoMed Announces Key Senior Leadership Appointments (GlobeNewswire) -5.16%
Nov-12-24 07:00AM	CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-08-24 09:55AM	CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup (GlobeNewswire)
Nov-07-24 08:30AM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 08:00AM	CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) (GlobeNewswire)
Oct-29-24 08:00AM	CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Oct-15-24 08:00AM	CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Oct-04-24 04:49PM	CervoMed Ends $20 Million Stock Sales Agreement with BTIG (TipRanks) +10.30% -6.20%
Oct-02-24 08:00AM	CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:00AM	CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) (GlobeNewswire) +5.81%
Sep-20-24 03:37AM	CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock? (Zacks)
Aug-27-24 08:30AM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.41%
Aug-22-24 08:00AM	CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies (GlobeNewswire)
Aug-12-24 08:00AM	CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +7.54%
Aug-04-24 09:03AM	Morgan Stanley Predicts up to ~230% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-30-24 08:00AM	CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-29-24 08:00AM	CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) (GlobeNewswire)
Jul-17-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference (GlobeNewswire) -6.73%
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.77%
Jul-11-24 08:51AM	CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 (GlobeNewswire) +5.64%
Jul-10-24 10:52AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-24-24 08:00AM	CervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-11-24 08:00AM	CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies (GlobeNewswire)
May-20-24 10:09AM	CervoMed Names William Elder CFO (MT Newswires) -18.06%
08:00AM	CervoMed to Appoint William Elder as Chief Financial Officer (GlobeNewswire)
May-15-24 09:54AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire) -5.10%
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Apr-01-24 08:00AM	CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-28-24 04:05PM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.76%
08:30AM	CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors (GlobeNewswire)
Mar-05-24 08:00AM	CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024 (GlobeNewswire)
Feb-21-24 08:00AM	CervoMed to Participate in the BIO CEO and Investor Conference (GlobeNewswire) -7.35%
Feb-20-24 10:22AM	CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board (News Direct) -6.73%
Feb-12-24 08:00AM	CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies (GlobeNewswire) +27.12%
Feb-07-24 08:30AM	CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board (GlobeNewswire) +8.58%
07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire)
Feb-06-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now (GlobeNewswire)
Feb-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 67 (GlobeNewswire)
Jan-10-24 07:00AM	Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream (GlobeNewswire)
Jan-09-24 07:00AM	Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now (GlobeNewswire)
Jan-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 66 (GlobeNewswire)
Nov-13-23 07:00AM	CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Oct-30-23 11:21AM	CRVO: New Data from Phase 2a Trial Presented at CTAD (Zacks)
Oct-25-23 02:50PM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies (PR Newswire) -5.44%
Oct-24-23 07:00AM	CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias (PR Newswire)
Oct-18-23 07:00AM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies (PR Newswire) +6.69%
Oct-05-23 07:00AM	CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference (PR Newswire)

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Winton Matthew	Chief Commercial and Business	Nov 17 '25	Buy	8.43	3,500	29,505	13,500	Nov 19 07:46 AM
Winton Matthew	Chief Commercial and Business	Nov 18 '25	Buy	7.95	1,500	11,925	15,000	Nov 19 07:46 AM
Gregoire Sylvie	Director	Nov 17 '25	Buy	8.46	10,807	91,427	12,500	Nov 19 07:45 AM
Gregoire Sylvie	Director	Nov 17 '25	Buy	8.46	10,793	91,309	1,484,078	Nov 19 07:45 AM
ELDER WILLIAM ROBERT	CFO, GC & Secretary	Nov 18 '25	Buy	8.32	2,500	20,800	12,500	Nov 19 07:45 AM
ELDER WILLIAM ROBERT	CFO, GC & Secretary	Nov 17 '25	Buy	8.45	1,000	8,450	10,000	Nov 19 07:45 AM
ALAM JOHN J	CEO & President	Nov 17 '25	Buy	8.46	10,807	91,427	1,484,078	Nov 19 07:45 AM
ALAM JOHN J	CEO & President	Nov 17 '25	Buy	8.46	10,793	91,309	12,500	Nov 19 07:45 AM
Gregoire Sylvie	Director	Nov 13 '25	Buy	7.51	4,447	33,397	1,471,578	Nov 17 09:02 AM
Gregoire Sylvie	Director	Nov 14 '25	Buy	7.57	1,707	12,922	1,473,285	Nov 17 09:02 AM
Gregoire Sylvie	Director	Nov 14 '25	Buy	7.55	1,693	12,782	1,693	Nov 17 09:02 AM
ALAM JOHN J	CEO & President	Nov 13 '25	Buy	7.51	4,447	33,397	1,471,578	Nov 17 09:01 AM
ALAM JOHN J	CEO & President	Nov 14 '25	Buy	7.57	1,707	12,922	1,707	Nov 17 09:01 AM
ALAM JOHN J	CEO & President	Nov 14 '25	Buy	7.55	1,693	12,782	1,473,271	Nov 17 09:01 AM
Winton Matthew	Chief Commercial and Business	Nov 14 '25	Buy	7.57	10,000	75,700	10,000	Nov 17 09:01 AM
Gregoire Sylvie	Director	Nov 12 '25	Buy	7.35	5,553	40,815	1,467,131	Nov 13 08:52 AM
ELDER WILLIAM ROBERT	CFO, GC & Secretary	Nov 12 '25	Buy	7.44	3,500	26,040	9,000	Nov 13 08:52 AM
ALAM JOHN J	CEO & President	Nov 12 '25	Buy	7.35	5,553	40,815	1,467,131	Nov 13 08:52 AM
ELDER WILLIAM ROBERT	CFO, GC & Secretary	May 14 '25	Buy	8.46	4,233	35,811	5,500	May 14 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

CRVO

CervoMed Inc

Upgrade your FINVIZ experience